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Abstract
Background: Co-receptor tropism (CRT) in patients with a long history of HIV-1 infection and antiretroviral
treatment has been rarely investigated to date. The aim of this study was to determine the prevalence of X4 and
R5 strains in patients with a >15-year follow-up and to investigate the demographical, viral, immunological, clinical
and therapeutic determinants of CRT in this population. The possible influence of CRT on the inflammation state
related to chronic HIV infection was also examined.
Methods: A total of 118 HIV-1 infected patients with an initial HIV-1-positive test before 1997, and still on follow-up,
were enrolled and consecutively submitted to blood sampling. Of these, 111 were on antiretroviral therapy and
89/111 (80.2%) had a plasma viral load (pVL) <25 copies/ml at testing. HIV-1 DNA was extracted and amplified
from PBMCs for env gp120 sequencing. CRT was assigned by using geno2pheno and isolates were classified as X4
(FPR ≤20%) or R5 (FPR >20%). Level of serological inflammation biomarkers including IL-6, hsPCR, and D-dimers
were measured.
Results: An X4 virus was evidenced in HIV-1 proviral DNA of 50 patients (42%) while the remaining 68 patients were
classified as R5. The median follow-up was 19 years (range 15–25). No association was observed between CRT and sex,
age, nationality, subtype, HIV risk factor, HBV/HCV co-infection, baseline CD4+ cell count and pVL, overall duration of
antiretroviral therapy, past exposure to mono-or dual therapies, and duration of NNRTI or PI-based therapy. The
presence of an X4 strain was associated with CD4 nadir (p = 0.005), CD4 absolute count over time (p < 0.001), and
cumulative positive (copy/years) viremia (p <0.001) during the whole patient history. No differences were found
between R5 and X4 patients regarding inflammation marker levels including Il-6, hsPCR and D-dimers.
Conclusions: An archived X4 virus was demonstrated in 42% of patients with a >15-year-history of HIV infection.
This presence was clearly associated with a greater exposure to positive viremia and a poorer CD4 trend over time
compared to R5, independent of type and duration of antiretroviral treatment. CRT does not seem to influence the
inflammation rate of patients aging with HIV.
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Background
The third variable (V3) region of gp120 is responsible
for the differential CXCR4 or CCR5 co-receptor binding
to HIV-1, and genotypic methods and bioinformatic
tools based on V3 sequencing have been developed to
facilitate the prediction of co-receptor tropism (CRT) [1].
The selective pressure leading to emergence of either
CXCR4-using (X4) or CCR5-using (R5) variants is complex
but its relevance in the HIV pathogenesis and natural
history remains only partially understood [2,3]. R5 variants
predominate during the acute phase [4], and also during
the asymptomatic phase of HIV-1 infection. Whether this
R5 predominance reflects a transmission bias [5] or a post-
transmission amplification bias (due to a higher proportion
of CCR5 +CD4+ T cells recruited during acute HIV-1
infection) [6], rather than a superior in vivo fitness of
R5 strains, remains uncertain. During the course of
infection, depending on the HIV-1 subtype and usually in
concomitance with the earliest signs of disease progression,
a proportion of patients experience the emergence of X4
variants [7]. However, this shift is unnecessary for AIDS
progression; in fact, it is observed in only about 50% of
subtype-B infected patients [8]. Moreover, also the time
span for seroconversion to AIDS does not differ signifi-
cantly between individuals with pure R5 variants and those
with non-R5 (pure X4 and dual-mixed, DM) variants [8].
Hence, this shift might be the consequence, rather than the
cause, of immunological deterioration which weakens the
selective pressure, thus promoting non-R5 variants in vivo.
Moreover, it is unknown if X4 variants emerge from latency
many years after an initial independent transmission or,
more likely, if they evolve from preexisting R5 variants
through a progressive acquisition of a broader receptor
affinity [9]. Most information is derived from studies of
patients evolving to AIDS in the pre-HAART era. If this
viral evolution can be modified by antiretroviral therapy
and by the consequent immune-reconstitution, is still a
point of dispute. When patients initiate antiretroviral
therapy (ART), both increased and decreased frequencies
of X4 viruses have been reported [10-14]; in addition,
even if the presence of CRT does not seem to predict
treatment success [15], recent cross-sectional studies
have demonstrated X4 strains in 40%-55% of patients with
antiretroviral exposure and therapy failure [16-19].
The prevalence of CRT in a population of patients with
a lengthy history of HIV-1 infection and antiretroviral
treatment has been rarely investigated. These patients,
even when administered highly effective ART regimens,
are persistently exposed to antigen-stimulation leading
to a peculiar condition of chronic inflammation and
hypercoagulability, both of which are involved in deter-
mining mechanisms of aging [20,21]. In fact, surrogate
biomarkers of chronic inflammation/hypercoagulability,
such as IL-6, HsPCR and D-dimer, are altered in
HIV-infected subjects compared to matched uninfected
controls, and correlate with the frequency of both AIDS
[22] and non-AIDS events [23-25] and also with overall
mortality. Moreover, these biomarker levels are
higher in HIV-infected individuals with detectable
HIV-1 RNA [23,26]. It is still unknown if X4 and R5
strains can differently affect the process of HIV-related
inflammation and aging.
The primary objective of the present study was to
determine the prevalence of X4 (non-R5) and R5 strains
in patients with HIV infection for more than 15 years
and to investigate the possible association of CRT with
the demographical, viral, immunological, clinical and
therapeutic data. The possible influence of CRT on the
inflammation state related to the long-lasting HIV infection




All HIV-1 infected patients testing HIV-1 positive before
1997 and still being followed at the Clinic of Infectious
Diseases, University of Bari, Italy were eligible for the
study. Clinical data were extracted from the database of
the institute and included: date of first HIV-positive test,
demographic data, information regarding risk factors for
HIV acquisition, onset of opportunistic infections (AIDS
events), CDC staging (revised 1993), non-AIDS events,
blood biochemical parameters, CD4+ cell count, plasma
HIV-1 viral load, clinical and therapeutic history and
reported side effects. The following diseases were
considered as serious non-AIDS events: acute myocardial
infarction, congestive heart failure, coronary artery disease
requiring drug treatment, coronary revascularization,
decompensated liver disease, deep vein thrombosis,
diabetes mellitus, end-stage renal disease, non-AIDS
cancer, peripheral arterial disease, pulmonary embolism,
and stroke [27]. A total of 118 patients were enrolled and,
after informed consent, consecutively subjected to blood
sampling for genotypic CRT testing. As most patients
were expected to have low or undetectable plasma viral
load, CRT was determined for all subjects on proviral
DNA which furnishes highly comparable results with
those from viral RNA [28]. Concurrently, patients were
also submitted to routine blood exams for the assessment
of immune-virological parameters (CD4+ cell count and
HIV viral load) and surrogate markers of inflammation
and aging (IL-6, hsPCR, D-dimers).
Gp120 sequencing and CRT assignment
HIV-DNA was extracted and amplified from PBMCs and
gp120 sequencing on proviral DNA was performed as
previously described [29]. Only one PCR product per
sample was subjected to standard population sequencing.
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Sequences were analyzed with Seqscape software v2.5
(Applied Biosystems, Foster City, CA). Nucleotide
mixtures were considered if the second highest peak
in the electropherogram was >25%. CRT was inferred with
the geno2pheno[coreceptor] algorithm (http://coreceptor.
bioinf.mpi-inf.mpg.de/), setting the false positive rate (FPR)
at 20%, and isolates were classified as R5 (FPR >20%) or
non-R5 (FPR ≤20%). Only clonal prediction was employed
for classifying sequences.
HIV-1 subtyping
The HIV subtype was assigned by phylogenetic analysis
(neighbor-joining method using Kimura two-parameter
distances and Simplot analysis) of pol (complete protease
and reverse transcriptase) (Viroseq HIV Genotyping Kit;
Applied Biosystems, Foster City, CA) and env sequences.
Markers of inflammation
Surrogate markers of inflammation and aging in
HIV-positive patients, including IL-6, HsPCR, and
D-dimers, were quantified on plasma samples coincident
with CRT using commercially available assays. As previous
reports [30] suggest a role for IL-7 in inducing viral
evolution towards X4 viruses in vitro, the level of this
interleukin was also measured. Plasma D-dimers were
quantified by means of enzyme-linked fluorescent
assay (Vidas D-Dimeri Exclusion II, Biomerieux) at the
central laboratory of the University-Policlinico Hospital of
Bari (normal values: 0–500 ng/ml). HsPCR, IL-6 and IL-7
were measured at the Infectious Diseases Laboratory by
commercially available assays (for hs-PCR: Biokit Quantes
CRP, normal values: 0–300 ng/ml; for IL-6: Boster
Biological Immunoleader, detection limit: 0.3 pg/ml, assay
range: 4.69 - 300 pg/ml; for Il-7: IDElisa Human IL-7, Labs
Biotechnology, Canada, detection limit: 16 pg/ml, assay
range:16–1024 pg/ml, respectively).
Statistical analysis
Descriptive statistics were produced for all variables. Mean
and standard deviation (SD) were calculated for normally
distributed variables, and median and interquartile range
(IQR) for non-normally distributed variables. The
Mann–Whitney test was used to compare X4 and R5
groups in terms of quantitative variables while the
Fisher exact test was adopted for categorical variables.
Multivariate mixed models were utilized to investigate
the relationship between the CD4 slope/VL over time
and CRT; models were adjusted for baseline values;
interaction between CRT and time was included.
Since inflammation marker measurements are subject
to detection limits (particularly lower detection limits),
interval regression was used to explore the association
of IL-6, IL-7, HsPCR, D-dimers and CRT (and other
variables), by means of the intreg command Stata after
log transformation (natural logarithm).
Stata computer software version 12.0 (Stata Corporation,
4905 Lakeway Drive, College Station, Texas 77845, USA)
was used for statistical analysis.
Ethics
The research did not require approval from the ethics
committee, according to the Italian law, since it was
performed as an observational study in the context of
normal clinical routines (art.1, leg. decree 211/2003).
However, all patients provided informed consent for the
use of their data for research purposes. Blood samples
were taken as part of standard patient care; DNA
samples and data were previously anonymized, according
to the requirements set by Italian Data protection Code
(leg. Decree 196/2003).
Results
Patient characteristics according to CRT
The 118 HIV-1-infected patients were mostly males
(74.5%) (88 men, 30 women) with a 19-year (range 15–25)
median infection duration (from first HIV-positive testing).
One-hundred eleven (94.1%) were on antiretroviral
therapy, 89 of whom (80.2%) had plasma viral load
(pVL) <25 copies/ml at time of testing.
A total of 50 (42%) patients showed a X4 virus in their
HIV-1 proviral DNA while the remaining 68 patients were
classified as R5. The patient characteristics according to
CRT are summarized in Table 1. No association was
observed between CRT and sex, age, nationality, subtype
(B versus non-B), risk factor for acquisition of HIV
infection, HCV and HBV co-infection. No patient
presented an AIDS-related opportunistic infection at
the time of the study; the proportion of patients with
a previous AIDS diagnosis was similar in the two
groups; R5 patients presented a slightly higher frequency
of previous or current non-AIDS events but this difference
was not statistically significant.
Association with viro-immunological parameters
No differences were observed between R5 and X4
patients either in pVL value at time of analysis, or in the
proportion of patients presenting an undetectable viral
load. Similarly, both the absolute and percentage CD4+ cell
count in the two groups were not statistically different, even
if X4 patients presented a median number of CD4 about
100 cells lower when compared to R5. On the contrary, the
presence of a X4 strain was significantly associated
with the nadir CD4 cell count (both absolute, p = 0.005
and percentage, p = 0.01); moreover, it was strictly
linked to the CD4 absolute count over time (p < 0.001)
(Figure 1a). In addition, patients carrying an archived X4
also showed a greater cumulative incidence of positive
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viremia (copy/years) (p < 0.001) during the entire >15-year
follow-up (Figure 1b).
Association with antiretroviral therapy
Only five patients were naive to antiretroviral therapy
(3 bearing an R5 virus and 2 a X4 virus); from information
stored in our database, these five patients did not
require therapy as they could be considered long-term
non-progressors. An additional two patients (both R5)
were not on treatment at time of analysis because of
a voluntary therapy interruption. In the remaining
patients, no association was noted between CRT and
overall duration (years) of antiretroviral therapy, past
exposure to mono/dual therapies, or duration of NNRTI
or PI-based therapy.
Markers of inflammation and aging
No differences were found between R5 and X4 patients
regarding Il-6 levels (p = 0.7), levels of hsPCR (p = 0.5)
and D-dimers (p = 0.6), nor was an association observed
with IL-7 levels (p = 0.5) (Table 2).
Il-6, D-dimers and hsPCR levels were not correlated with
the presence of detectable HIV-RNA at time of testing, nor
with the cumulative viremia over time. Secondary adjusted
analyses were performed to test whether markers were dif-
ferent according to CRT (R5 vs X4) and viremia (viremic vs
aviremic) when tested for interaction, but no significant
results were found (Figure 2) Moreover, none of the
markers resulted associated with age. Only for IL-6 was a
certain association found with the CD4 count at time of
testing (β[per 100 CD4] = 0.023, 95% CI −0.05-0.0006,
p = 0.056) and the cumulative CD4 count over time (β[per
100 CD4] = 0.002, 95% CI −0.004- -0.00012; p = 0.03). No
biomarker demonstrated a correlation with the frequency
of previous or current AIDS and non-AIDS related events.
Analysis with different FPR cut-offs
In order to evaluate the potential impact of the chosen FPR
cut-off on the final outcome, data were also analyzed setting
the FPR at 10% and 5%; also in this case, no association
was observed between X4 and R5 patients and levels of
inflammation markers; once more, the only variable which
resulted associated with CRT was the CD4 nadir, either
when using a 10% FPR (both absolute, p = 0.002 and
percentage, p = 0.004) or a 5% FPR cut-off (both absolute,
p = 0.004 and percentage, p = 0.001).
Discussion
In the pre-HAART era, many studies demonstrated that SI
and/or X4 viruses emerged in approximately 40%–50% of
patients progressing to AIDS, suggesting that these
variants were associated with a worse clinical and
viro-immunological outcome [8]. More recently, this
percentage was found to range from 10% to 20% in
naïve patient cohorts [31-33] and from 40% to 50% in
multi-failed heavily-treated patients from maraviroc
registrative trials [17-19,34], including a small proportion
(1%-4%) of pure X4 and a large majority of R5/X4
(dual mixed, DM) strains.
Herein, we focused on patients surviving chronic HIV
infection for at least 15 years with a long history of
suppressed viremia under antiretroviral therapy in the
majority, high CD4 median level, and no opportunistic
infection at time of analysis. The results indicate that,
also in this population, >40% of patients presented an
archived X4 virus in proviral DNA, a percentage which is
similar, or even higher, when compared to other recent
reports [35,36] in suppressed patients with a shorter
history of viremia suppression. Therefore, examining
DNA for CRT determination should be recommended for
Table 1 Patient characteristics according to CRT
R5 X4 p value
N patients 68 (58%) 50 (42%)
Male gender (N,%) 52 (76%) 36 (72%) 0.6
Age (years, mean ± SD) 51.2 ± 5.6 50.6 ± 5.9 0.1
Foreign nationality (N,%) 1 (1.5%) 1 (2.0%) 0.8
HIV-1 non B subtype (N,%) 15 (22%) 7 (14%) 0.3
Risk factor (N,%)
- parenteral 44 (65%) 27 (54%)
- sexual 23 (34%) 21 (42%) 0.4
ART duration
(years; median, IQR)
13 (9–16) 14 (10–16) 0.5
- NRTIs 13 (9–16) 14 (10–16) 0.6
- NNRTIs 4 (1–7) 4 (2–6) 1.0
- PIs 7 (5–9) 6 (5–12) 0.5
Past use of mono- or
bi-therapy (N,%)
43 (63%) 35 (70%) 0.8
Previous AIDS events (N,%) 7 (10%) 10 (20%) 0.2
Serious non-AIDS
events (N,%)
19 (39%) 7 (14%) 0.07
HBsAg pos (N,%) 9 (13%) 4 (8%) 0.1
Anti-HCV pos (N,%) 51 (75%) 30 (60%) 0.1
pVL (log10 cp/ml;median, IQR) 3.2 (3.2-4.8) 4.1 (3.2-8.9) 0.1
Aviremic pts (N,%) 53 (78%) 36 (72%)
CD4+ cell count
(median, IQR)
- absolute (n/mmc) 658 (219–185) 558 (109–1219) 0.1
- percentage (%) 31 (24–53) 28 (11–52) 0.1
Nadir CD4+ cell count
- absolute (median
n/mmc;, IQR)
137 (90–616) 87 (27–382) 0.005
- percentage (%) 11 (7–27) 8 (2–32) 0.01
Legend: N = number, SD = standard deviation; IQR = InterQuartile Range; pVL:
HIV-1 plasma viral load.
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all patients before prescription of chemokine inhibitors.
Although the proportion of X4-carrying patients might be
overestimated in DNA with respect to plasma [37],
recent studies confirm that tropism switches under
ART suppression are rare. Therefore, the current proviral
DNA can be considered a good mirror of the patient viral
quasispecies, including both recent or former replication
variants [28,36].
Not only was a correlation with CD4 nadir evidenced,
in agreement with previous studies [35], but X4 variants
were significantly associated with exposure to higher
cumulative viral loads and poorer immunological control
over time, rather than with the viro-immunological state
at time of testing. From the design of the study, it is not
possible to resolve the pending question of whether X4
viruses emerged (and were archived in proviral DNA)
as a consequence of the continuous replication and
immunological impairment or, on the contrary, were
responsible for disease progression in these patients.
Even if several successive regimens might have masked the
actual impact of therapy on CRT, according to other publi-
cations [35], the duration and type of antiretroviral therapy
did not seem to influence CRT in our series. This finding
also confirms our previous observation that, in patients
treated by HAART and sequentially tested for CRT, the
co-receptor shift is independent of virological success [15].
None of the baseline demographic and clinical
characteristics, apart from CD4 and viral load trends
over time, seem to influence the predominant strain
archived in proviral DNA. In particular, even if the risk
factor for HIV acquisition might be a determinant for
CRT selection at time of transmission [38], it seems to lose
its importance over time. A lower proportion of X4
strains has been observed among some non-B-subtypes, in
particular subtype C [39], suggesting a possible association
with an improved virological outcome for non-B patients
when excluding racial and social variables, as recently
described by some authors [40,41]; in the present
study, however, non B-subtypes were rare and no definite
conclusion can be drawn concerning the relationship
between CRT and viral subtype. Moreover, the co-infection
with other viruses, in particular with HBV and HCV, failed
to demonstrate any association with CRT. In HIV-HCV
co-infection, the env gp120 of HIV was supposed to
interact with HCV E2 in triggering the apoptosis
mechanisms [42] to modulate the biology of human
hepatic stellate cells which play a key role in the fibrosis
pathogenesis [43], and to enhance the replication of HCV
through the engagement of extracellular coreceptors on
hepatocytes [44]. In this study, a slightly higher proportion
of R5 patients was observed among the HCV-positive
patients when compared to negatives, but without statis-
tical significance. If R5 and X4 strains can be differentially
Table 2 Lack of association of CRT with inflammatory





Lower limit Upper limit p
valueCI 95% CI 95%
hsPCR (log) 62 0.501 −1.219 2.22 0.57
D-dimers (log) 0 0.280 −1.336 0.777 0.60
IL-6 levels (log) 23 0.022 −0.175 0.131 0.78
IL-7 levels (log) 89 0.259 −1.184 0.666 0.58
N: number of patients; limit: detection limit of the assay; β: coefficient of
interval regression; CI: confidence interval.
Since inflammation marker measurements are subject to lowe
r detection limits, the association of IL-6, IL-7, HsPCR, D-dimers and CRT was
analyzed with interval regression by means of the intreg command Stata after
log transformation (natural logarithm). None of the markers resulted




Figure 1 Association of CRT with CD4 absolute count over time (a) and HIV cumulative viremia (b). Legend: x axis (time) = years; y axis:
a): CD4 = n/mmc, b): cumulative viremia = HIV-RNA log10 copy/years. The graph represents mean CD4 and HIV viral load (and standard errors)
over time for R5 and X4 groups, predicted from multivariate mixed models including patient as “clustering” variable and time from first HIV testing
(with quarters as unit of analysis), adjusting for baseline values (see Statistical methods). The red dashed line (Figure 1b) indicates the level of HIV
RNA <500 copies/ml (2,69 log).
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involved in determining viral persistence and fibrosis
progression in HCV positive patients should be object
of further research. No differences in AIDS-related
and serious non-AIDS events were observed in the
two groups, but, as only long surviving patients were
included in the study, pathological events leading to
death were not considered and therefore we cannot
exclude that severe AIDS occurrences might be variously
distributed in X4 and R5 patients.
Many reports indicate that HIV-infected patients
develop an inflammation and hypercoagulation state
which is involved in the aging mechanisms. Surrogate
serological markers such as IL-6, D-dimers and hsPCR
have been demonstrated to be good prognostic markers
in HIV-infected patients and are generally associated
with elevated HIV-1 viral loads [23-26]. It has been
hypothesized that X4-patients present an accelerated
rate of disease progression compared to R5. In fact, also
in our patient cohort aging with HIV, the presence of
X4 strains was associated with a poorer immunological
and virological control over time; therefore, we evaluated
the hypothesis that CRT might be correlated with a
worsened inflammation state as measured by the above
mentioned surrogate markers. However, HsPCR, D-dimer
and IL-6 s levels did not differ between the two groups of
R5 and X4 patients. Therefore, in our experience, CRT
did not seem to affect the inflammation state in patients
aging with HIV, at least when measured by means of sur-
rogate markers. None of the other patient characteristics
was predictive of higher levels of IL-6, HsPCR and
D-dimers in our cohort, except for a lower current
and cumulative CD4 cell count for IL-6, which would
seem to suggest, according to other studies [45], that
immune-depression is an essential driving force for
inflamm-aging in HIV positive patients. A limitation of our
findings is represented by the fact that surrogate markers
do not show any difference according to age or, more
importantly, between patients with active HIV replication
a b
c
Figure 2 Association of inflammation markers with CRT in viremic and aviremic patients. Secondary adjusted analyses were performed to
test whether markers were different according to CRT (R5 vs X4) and viremia (viremic vs aviremic), and both together (test for interaction). Results
are showed as: a) and b): box and whiskers plot for log D-dimer (ng/ml) and log hs-PCR (ng/ml) (continuous variables), respectively, with
breakdown for CRT, separately for viremic and aviremic patients; c) bar graph for IL-6 (pg/ml)(ordinal variable), with breakdown for CRT, separately
for viremic and aviremic patients. No significant results were found.
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compared to those with undetectable viraemia. This is most
likely due to the particular characteristics of our population
which included patients with a narrow age range (median
50, IQR 47–53 years) and only a limited number of subjects
with detectable HIV-RNA (25%). Moreover, although IL-7
was demonstrated to induce viral evolution of X4 viruses
in vitro [30], no association between current IL-7
levels and the presence of archived X4 variants
in vivo was observed in the present study; however, it
cannot be excluded that lymphopenia-induced IL-7
production might have previously favored the R5 to
X4 switch at previous timepoints during the patient’s
history, but this association was not apparent at time
of analysis.
Lastly, the issue concerning the clinically relevant FPR
cut-off for CRT attribution based on geno2pheno is still
controversial; herein, according to the 2011 European
Guidelines [46], the 20% FPR cut-off was chosen since
interpretation was based on a single DNA amplification
and sequencing; however, similar results were also
obtained when data were analyzed using a 10% and a 5%
cut-off, excluding the potential impact of this choice on
the final outcome of the analysis.
This is one of the few studies regarding CRT in
patients aging with HIV (all patients living at the time of
study design have been included) and the first, to our
knowledge, which investigates the relationship between
the CRT and state of inflammation. However, the study
presents several limitations. All the above reported lack
of associations might be due to a sample of insufficient
size to detect small effects, particularly in subgroup
analyses, interactions and multivariable adjustments.
Furthermore, due to its retrospective design, some
relevant baseline characteristics might not have been
measured: for instance, for some of the older patients,
baseline viral load was not available (before 1995); in
fact, cumulative viral load is probably underestimated
for all patients. Also, repeated and prospectively col-
lected measurements of inflammation markers were
not performed, and we can only estimate the influ-
ence of point determination of these parameters.
Finally, as already stated, patients have been “naturally”
selected on the basis of their vital status at time of
CRT testing, and it must be kept in mind that patients
with a shorter HIV history might differ from this highly
selected population.
Conclusions
A significant proportion (42%) of patients with a
>15 year history of HIV infection had an archived X4
virus. This presence was clearly associated with a
longer duration of exposure to positive viremia and
with a poorer CD4 trend over time when compared
to R5, independent of the duration of antiretroviral
treatment, even if a causal relationship could not be
established. The CRT does not seem to influence the
inflammation rate of patients aging with HIV.
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